ADVM - Adverum Biotechnologies Inc Stock Price, Fair Value and News

8.15USD+0.06 (+0.74%)Market Closed

Market Summary

USD8.15+0.06

Market Closed

0.74%

ADVM Alerts

1 major insider buys recently.

ADVM Stock Price

View Fullscreen

ADVM RSI Chart

ADVM Valuation

Market Cap

167.9M

Price/Earnings (Trailing)

-1.49

Price/Sales (Trailing)

50.62

EV/EBITDA

-0.17

Price/Free Cashflow

-1.81

ADVM Price/Sales (Trailing)

ADVM Profitability

EBT Margin

-3166.42%

Return on Equity

-61.93%

Return on Assets

-42.15%

Free Cashflow Yield

-55.11%

ADVM Fundamentals

ADVM Revenue

Revenue (TTM)

3.6M

ADVM Earnings

Earnings (TTM)

-112.9M

Earnings Growth (Yr)

14.69%

Earnings Growth (Qtr)

-4.52%

Breaking Down ADVM Revenue

Last 7 days

-14.4%

Last 30 days

17.4%

Last 90 days

-11.7%

Trailing 12 Months

-58.8%

How does ADVM drawdown profile look like?

ADVM Financial Health

Current Ratio

9.24

ADVM Investor Care

Shares Dilution (1Y)

106.38%

Diluted EPS (TTM)

-10.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	3.6M	3.6M	3.6M	3.6M
2021	3.6M	5.5M	6.5M	7.5M
2019	0	0	1.6M	2.6M
2018	7.5M	7.6M	7.9M	7.5M
2017	1.7M	1.8M	1.9M	1.8M
2016	2.4M	2.5M	1.9M	1.5M
2015	745.0K	813.0K	1.6M	2.3M
2014	210.0K	195.0K	369.0K	572.0K
2013	142.5K	255.0K	367.5K	480.0K
2012	0	0	0	30.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

CEO	Dr. Laurent Fischer
WEBSITE	https://adverum.com
INDUSTRY	Biotechnology
EMPLOYEES	123

Adverum Biotechnologies Inc Frequently Asked Questions

What is the ticker symbol for Adverum Biotechnologies Inc? What does ADVM stand for in stocks?

ADVM is the stock ticker symbol of Adverum Biotechnologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adverum Biotechnologies Inc (ADVM)?

As of Thu Jul 25 2024, market cap of Adverum Biotechnologies Inc is 167.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADVM stock?

You can check ADVM's fair value in chart for subscribers.

Is Adverum Biotechnologies Inc a good stock to buy?

The fair value guage provides a quick view whether ADVM is over valued or under valued. Whether Adverum Biotechnologies Inc is cheap or expensive depends on the assumptions which impact Adverum Biotechnologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADVM.

What is Adverum Biotechnologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ADVM's PE ratio (Price to Earnings) is -1.49 and Price to Sales (PS) ratio is 50.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADVM PE ratio will change depending on the future growth rate expectations of investors.